ICAM1 and neoplasm: Additionally, it has been reported that ICAM-1 on TAMs could bind CD18 on Myeloma cells to regulate drug resistance [139], and this contact-dependent interaction tended to expand M2 infiltration and release cells from tumor cell aggregates [181].